CN102166274B - Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis - Google Patents
Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis Download PDFInfo
- Publication number
- CN102166274B CN102166274B CN2011100454509A CN201110045450A CN102166274B CN 102166274 B CN102166274 B CN 102166274B CN 2011100454509 A CN2011100454509 A CN 2011100454509A CN 201110045450 A CN201110045450 A CN 201110045450A CN 102166274 B CN102166274 B CN 102166274B
- Authority
- CN
- China
- Prior art keywords
- water
- elution
- methanol
- active
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title claims abstract description 12
- 239000003888 alpha glucosidase inhibitor Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 10
- 210000000813 small intestine Anatomy 0.000 title abstract description 9
- 241000580938 Sapindus Species 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000010828 elution Methods 0.000 claims abstract description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 9
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 239000004793 Polystyrene Substances 0.000 claims abstract description 5
- 229920002223 polystyrene Polymers 0.000 claims abstract description 5
- 230000000968 intestinal effect Effects 0.000 claims description 16
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 8
- 230000009514 concussion Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000452 restraining effect Effects 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 240000003377 Shepherdia canadensis Species 0.000 abstract 2
- 235000018324 Shepherdia canadensis Nutrition 0.000 abstract 2
- 239000000401 methanolic extract Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for extracting a small intestine alpha-glucosidase inhibitor from soapberry, which is characterized in that shells of dried soapberry fruits are crushed, the average particle size is 200-350 mu m, 50-70% methanol is added according to the material-liquid ratio of 1 g: 40-50 ml, the mixture is shaken and extracted at room temperature for 18-24 hours, supernatant is separated, and methanol extract is obtained through concentration and drying, wherein the yield is 25-30%; dispersing the methanol extract into distilled water, wherein the material-liquid ratio is 1 g: 30-40 ml, adding ethyl acetate according to the volume ratio of 1: 2, performing shake extraction for 2-3 times, and collecting water phase raffinate; concentrating the aqueous phase raffinate' to 15-20 ml, loading on a polystyrene type weak-polarity macroporous adsorption resin Diaion HP-20 chromatographic column, performing gradient elution by using water-methanol at the concentration of 0, 50% and 100% and the elution flow rate of 1ml/min, and collecting an active elution peak; concentrating the components with the active water elution peak to 4-5 ml, loading the components on a Sephadex LH-20 column, eluting the components with water at the elution flow rate of 0.5ml/min, collecting the active water elution peak, concentrating and drying to obtain the active ingredient of the small intestine alpha-glucosidase inhibitor, wherein the height of the filler is 50cm, and the diameter of the column is 3.2cm, and the active water elution peak is obtained, and the yield is 0-15%.
Description
Technical field
The present invention relates to from Fructus Sapindi Mukouossi, extract the method for small intestinal alpha-glucosidase inhibitor, belong to Chinese herbal medicine preparation and chemical technology field.
Background technology
Postprandial hyperglycemia is the risk factor of type ii diabetes and metabolic syndrome always, and the control post-prandial glycemia has great importance to diabetics undoubtedly.Under physiological status, all there is alpha-glucosidase (EC 3.2.1.20) at small intestinal in the main absorption site of glucose in the mucosa brush border that the small intestinal upper, middle and lower are three sections, this enzyme is a kind of mammal digestive enzyme.Polysaccharide trans-oral saliva in the food, pancreatic amylase are digested to oligosaccharide, disaccharidase and the trisaccharide that contains a small amount of glucose molecule, get into the small intestine meridian alpha-glucosidase and are hydrolyzed to single glucose, are absorbed into blood by small intestinal, are the main causes that post-prandial glycemia raises.Therefore, be the activity of the inhibitor of target spot with the alpha-glucosidase through this enzyme of adjusting, can brush digestion and the absorption that the edge stops carbohydrate at intestinal villi, thereby weaken the peak value of post-prandial glycemia, prevent postprandial hyperglycemia.Compare with other OHA and insulinize, the notable attribute of alpha-glucosidase inhibitor is effectively to stop the post-prandial glycemia of diabetics to raise, and makes patient's blood glucose steadily and lentamente maintain certain level, improves the glucostasis index.The inhibitor acarbose of typical alpha-glucosidase has been recommended as a line medicine of treatment type ii diabetes at present by domestic clinician; But digestive tract side effects such as flatulence are obvious, are the domestic and international research focuses so from natural plants, extract the alpha-glucosidase inhibitor of high-efficiency low-toxicity always.More existing at present relevant report and patents of extracting about alpha-glucosidase inhibitor, but do not see that relevant report and the patent of from Fructus Sapindi Mukouossi, extracting alpha-glucosidase inhibitor arranged.
Summary of the invention
The objective of the invention is to be directed against the deficiency of prior art and the method for from Fructus Sapindi Mukouossi, extracting the small intestinal alpha-glucosidase inhibitor is provided, be characterized in that raw material sources are wide, simple to operate, suppress the efficient height.
The object of the invention has following technical measures to realize that wherein said raw material umber is parts by weight except that specified otherwise.
The method of from Fructus Sapindi Mukouossi, extracting the small intestinal alpha-glucosidase inhibitor may further comprise the steps:
(1) shell of dry Fructus Sapindi Mukouossi fruit is pulverized, particle mean size is 200～350 μ m, and adding concentration by solid-liquid ratio 1g: 40～50ml is 50～70% methanol; Concussion was at room temperature extracted 18～24 hours; Separation of supernatant, concentrate drying get methanol extractum, and yield is 25～30%;
(2) above-mentioned methanol extractum is scattered in the distilled water, solid-liquid ratio is 1g: 30～40ml, adds ethyl acetate then in 1: 2 by volume, and the water raffinate is collected in concussion extraction 2～3 times;
(3) above-mentioned water raffinate ` is concentrated to 15～20ml; Last polystyrene type low pole macroporous adsorbent resin DiaionHP-20 chromatographic column is used the water-methanol gradient elution, and concentration is 0,50%, 100%; Elution flow rate is 1ml/min, collects to have active eluting peak;
(4) above-mentioned component with activated water eluting peak is concentrated to 4～5ml, last Sephadex LH-20 post, the high 50cm of filler; Column diameter 3.2cm; Use water elution, elution flow rate is 0.5ml/min, collects to have active water elution peak; Get the small intestinal alpha-glucosidase restraining agent effective ingredient behind the concentrate drying, yield is 10～15%.
Performance test
The detection method of active eluting peak: eluting is partly launched with the thin-layer silicon offset plate of 0.2mm, and developing solvent is a chloroform: methanol: water=6: 4: 1.With the colour developing of 5% sulphuric acid spraying post-heating, the Rf value with high activity eluting peak is 0.2～0.3.
The present invention has following advantage:
(1) technology is simple, easy to operate;
(2) suppress active strong.Experiment showed, that when 0.2mg/ml concentration, the extract of this experiment arrives 92.5% and 90.2% respectively, IC to the suppression ratio of small intestinal alpha-glucosidase sucrose and maltose hydrolysing activity
50Value is respectively 31.3 μ g/ml and 33.1 μ g/ml.
The specific embodiment
Through embodiment the present invention is carried out concrete description below, be necessary to be pointed out that at this present embodiment only is used for the present invention is further specified, can not be interpreted as restriction protection domain of the present invention.The person skilled in the art in this field can make some nonessential improvement and adjustment to the present invention according to the content of the invention described above.
Embodiment 1:
(1) get the powder 10g of dry Fructus Sapindi Mukouossi fruit, particle mean size is 200 μ m, and adding concentration by solid-liquid ratio 1g: 40ml is 50% methanol 400ml, and concussion was at room temperature extracted 18 hours, separation of supernatant, and concentrate drying gets methanol extractum 2.6g;
(2) press solid-liquid ratio 1g: 30ml, above-mentioned methanol extractum is scattered in the 78ml distilled water, added 156ml ethyl acetate concussion extraction 2 times again in 1: 2 by volume, extract is separated with the water extract;
(3) above-mentioned aqueous portion is concentrated to 16ml, last macroporous adsorption resin chromatography post, and the high 50cm of filler, column diameter 4cm uses the water-methanol gradient elution, and flow velocity is 1ml/min, and concentration is 0,50%, 100%.Collect eluent, detect, getting the strongest active position is 100% water elution peak;
(4) above-mentioned component with activated water eluting peak is concentrated to 5ml, last Sephadex LH-20 post, the high 50cm of filler, column diameter 3.2cm uses water elution, and elution flow rate is 0.5ml/min.The fraction collection eluent, collection has active water elution peak, gets white solid 1.2g behind the concentrate drying.
Embodiment 2:
(1) get the powder 10g of dry Fructus Sapindi Mukouossi fruit, particle mean size is 300 μ m, and adding concentration by solid-liquid ratio 1g: 50ml is 60% methanol 500ml, at room temperature shook 20 hours, and separation of supernatant, and with obtaining methanol extractum 2.9g after the supernatant concentration drying;
(2) press solid-liquid ratio 1g: 40ml, above-mentioned methanol extractum is scattered in the 116ml distilled water, added 232ml ethyl acetate concussion extraction 3 times again in 1: 2 by volume, extract is separated with the water extract;
(3) above-mentioned aqueous portion is concentrated to 18ml, last polystyrene type low pole macroporous adsorbent resin Diaion HP-20 chromatographic column, and the high 50cm of filler, column diameter 4cm uses the water-methanol gradient elution, and elution flow rate is 1ml/min, and concentration is 0,50%, 100%.Collect eluent, detect, getting the strongest active position is 100% water elution peak;
(4) above-mentioned component with activated water eluting peak is concentrated to 6ml, last Sephadex LH-20 post, the high 50cm of filler, column diameter 3.2cm uses water elution, and elution flow rate is 0.5ml/min.The fraction collection eluent, collection has active water elution peak, gets white solid 1.3g behind the concentrate drying.
Embodiment 3:
(1) get the powder 10g of dry Fructus Sapindi Mukouossi fruit, particle mean size is 350 μ m, and adding concentration by solid-liquid ratio 1g: 50ml is 70% methanol 500ml, at room temperature shook 24 hours, and separation of supernatant, and with obtaining methanol extractum 3.0g after the supernatant concentration drying;
(2) press solid-liquid ratio 1g: 30ml, above-mentioned methanol extractum is scattered in the 90ml distilled water, added 180ml ethyl acetate concussion extraction 3 times again in 1: 2 by volume, extract is separated with the water extract;
(3) above-mentioned aqueous portion is concentrated to 20ml, last polystyrene type low pole macroporous adsorbent resin Diaion HP-20 chromatographic column, and the high 50cm of filler, column diameter 4cm uses the water-methanol gradient elution, and elution flow rate is 1ml/min, and concentration is 0,50%, 100%.Collect eluent, detect, getting the strongest active position is 100% water elution peak;
(4) above-mentioned component with activated water eluting peak is concentrated to 5ml after, last Sephadex LH-20 post, the high 50cm of filler, column diameter 3.2cm uses water elution, elution flow rate is 0.5ml/min.The fraction collection eluent, collection has active water elution peak, gets white solid 1.5g behind the concentrate drying.
Application example 1
Following by the Fructus Sapindi Mukouossi extract that obtains in the foregoing description to small intestinal alpha-glucosidase inhibition activity test method and result:
Order rat small intestine acetone extraction powder from SIGMA company, (pH7.0) homogenized is removed supernatant after centrifugal for PBS, 0.1M with phosphate buffer; The mixed liquor homogenized of reuse PBS+10%Triton, centrifugal back obtains supernatant.After dialyzer dialysis in 24 hours, to obtain the thick alpha-glucosaccharase enzymatic solution of rat small intestine.The sucrose of the thick enzymatic solution of rat small intestine alpha-glucosidase and maltose hydrolysing activity are respectively 0.38U/ml and 1.85U/ml.Wherein enzyme activity unit is defined as: under 37 ℃, pH6.8 condition, under the effect of enzyme, decomposed 1 μ mol sucrose or maltose in 1 minute, be defined as an enzyme activity unit (U).
The active enzyme reaction mixed solution of sucrose hydrolysis of measuring the small intestinal alpha-glucosidase comprises: the thick solution of rat small intestine alpha-glucosidase (0.2ml), Fructus Sapindi Mukouossi extract (0.1ml; Water-soluble), sucrose solution (0.2ml, 56mM sucrose is dissolved in the phosphate buffer of 0.1M pH6.3).
The enzyme reaction mixed solution of measuring the maltose hydrolysing activity of small intestinal alpha-glucosidase comprises: the thick solution of rat small intestine alpha-glucosidase (0.05mL), Fructus Sapindi Mukouossi extract (0.1ml; Water-soluble), maltose solution (0.35ml, 3.5mM maltose is dissolved in the phosphate buffer of 0.1M pH6.3).
Above reaction mixture was reacted 15 minutes in 37 ℃ of incubators, stop the hydrolysis of enzyme with the Tris-Hcl solution of 0.75ml.With glucose oxidase method (GOD method), be determined at the OD value under the 490nm wavelength, active with the cubage alpha-glucosidase inhibition of glucose.
Suppress percentage rate=[1-(the blank light absorption value of extract light absorption value-extract)/enzyme light absorption value alive] * 100%.
Test result is as shown in table 1:
Table 1 Fructus Sapindi Mukouossi extract suppresses active to the small intestinal alpha-glucosidase
Claims (1)
1. from Fructus Sapindi Mukouossi, extract a kind of method of small intestinal alpha-glucosidase inhibitor, it is characterized in that this method may further comprise the steps: `
(1) shell of dry Fructus Sapindi Mukouossi fruit is pulverized, particle mean size is 200～350 μ m, and adding concentration by solid-liquid ratio 1g: 40～50ml is 50～70% methanol; Concussion was at room temperature extracted 18～24 hours; Separation of supernatant, concentrate drying get methanol extractum, and yield is 25～30%;
(2) above-mentioned methanol extractum is scattered in the distilled water, solid-liquid ratio is 1g: 30～40ml, adds ethyl acetate then in 1: 2 by volume, and the water raffinate is collected in concussion extraction 2～3 times;
(3) above-mentioned water raffinate ` is concentrated to 15～20ml; Last polystyrene type low pole macroporous adsorbent resin DiaionHP-20 chromatographic column is used the water-methanol gradient elution, and concentration is 0%, 50%, 100%; Elution flow rate is 1ml/min, collects to have active 100% water elution peak;
(4) above-mentioned component with activated water eluting peak is concentrated to 4～5ml, last Sephadex LH-20 post, the high 50cm of filler; Column diameter 3.2cm; Use water elution, elution flow rate is 0.5ml/min, collects to have active water elution peak; Get the small intestinal alpha-glucosidase restraining agent effective ingredient behind the concentrate drying, yield is 10～15%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100454509A CN102166274B (en) | 2011-02-25 | 2011-02-25 | Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100454509A CN102166274B (en) | 2011-02-25 | 2011-02-25 | Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166274A CN102166274A (en) | 2011-08-31 |
| CN102166274B true CN102166274B (en) | 2012-05-23 |
Family
ID=44487717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100454509A Expired - Fee Related CN102166274B (en) | 2011-02-25 | 2011-02-25 | Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166274B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143464A1 (en) * | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
| US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
-
2011
- 2011-02-25 CN CN2011100454509A patent/CN102166274B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166274A (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102413705B1 (en) | Composition for improving liver function comprising Dendropanax morbifera extract | |
| CN102389385B (en) | Herba portulacae extract and solution, and preparation method and application | |
| CN102702163B (en) | Method for preparing high-purity monomer epigallocatechin gallate from processed leftovers of tea leaves | |
| CN111671765B (en) | Application of brown algae dietary fiber in preparation of medicines, foods and/or health care products for treating or preventing metabolic syndrome | |
| CN101585885A (en) | Method for preparing polygonatum odoratum polysaccharide | |
| CN101497906A (en) | Separation and purification preparation as well as hypoglycemic activity of tea polysaccharide | |
| CN106215010B (en) | A kind of extraction method of highland barley polyphenol | |
| CN102924536A (en) | Preparation method of strawberry polyphenol | |
| CN104127463A (en) | Echinacea extract product, preparation method and application thereof | |
| CN111870659A (en) | Application of enzymatic hydrolyzed grain bran extract in preparation of DPP-4 inhibitor | |
| WO2017148414A1 (en) | Fucoidan, preparation method therefor, and uses thereof | |
| CN116987056A (en) | Method for extracting dihydroquercetin from larch | |
| CN102805198A (en) | Method for extracting active protein from rough old tea | |
| CN101787361A (en) | Rutin hydrolase, preparation method and application thereof | |
| CN102942637A (en) | Method for increasing extraction rate of wide cactus polysaccharide | |
| CN114773495B (en) | Method for preparing Fuzhuan tea polysaccharide with blood sugar and blood lipid reducing functions | |
| US11298395B2 (en) | Isolates from spent turmeric for the management of rheumatoid arthritis | |
| CN102166274B (en) | Method for extracting small intestine α-glucosidase inhibitor from Sapindus chinensis | |
| CN118178585B (en) | Preparation method and application of preparation for treating hyperuricemia and gout | |
| CN101235068B (en) | Method for preparing hederacoside C from bindwood | |
| CN102875691B (en) | Method for synchronously preparing active substances from tea dregs | |
| CN113527326A (en) | Preparation method and application of ellagitannin compound castacrenin D | |
| CN105708894A (en) | Method for preparing walnut green husk polyphenol from fresh walnut green husks | |
| CN102266360A (en) | Method for extracting alpha-glucosaccharase inhibitor from Fructus Terminaliae Immaturus | |
| CN101445456A (en) | Method for extracting and separating chlorogenic acid from chrysanthemum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20150225 |
|
| EXPY | Termination of patent right or utility model |